FDA hands In­di­a's Nat­co Phar­ma an­oth­er 483, with eight ob­ser­va­tions cit­ed 

In­di­an man­u­fac­tur­er Nat­co Phar­ma has been hit with an­oth­er 483, fol­low­ing an FDA in­spec­tion made at its phar­ma man­u­fac­tur­ing fa­cil­i­ty, lo­cat­ed at 509 228 Telan­gana, In­dia, be­tween Oct. 9 and Oct. 18 this year.

The 26-page in­spec­tion re­port was is­sued to the man­u­fac­tur­er on Oct. 18 and was pub­lished on Wednes­day, out­lin­ing eight ob­ser­va­tions.

Equip­ment was not prop­er­ly as­signed to the cor­rect per­son­nel and was op­er­at­ed by unau­tho­rized em­ploy­ees, in­clud­ing equip­ment used to man­u­fac­ture batch­es of prod­ucts for the US mar­ket, the Form 483 said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER